Prediction of the interaction of HIV-1 integrase and its dicaffeoylquinic acid inhibitor through molecular modeling approach

Ethnicity and Disease

Volumn 20, Issue 1 SUPPL.1, 2010, Pages

  Hu, Zengjian ^a   Chen, Dagang ^b   Dong, Lanxiang ^b   Southerland, W M ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b Amina International Inc   (United States)

Author keywords

Anti AIDS drug; Dicaffeoylquinic acids; HIV 1 integrase; Molecular modeling

Indexed keywords

DICAFFEOYLQUINIC ACID; DICAFFEOYLQUINIC ACID DERIVATIVE; INTEGRASE INHIBITOR; PROTEIN INHIBITOR; QUINIC ACID; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; CAFFEOYLQUINIC ACID; DRUG DERIVATIVE; INTEGRASE; P31 INTEGRASE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CONFERENCE PAPER; DRUG DESIGN; ENZYME INHIBITOR INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR MODEL; PREDICTION; VIRUS INHIBITION; VIRUS REPLICATION; ARTICLE; BIOLOGY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVE SITE; PHYSIOLOGY; PROTEIN BINDING; STRUCTURE ACTIVITY RELATION; VIRUS DNA CELL DNA INTERACTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CATALYTIC DOMAIN; COMPUTATIONAL BIOLOGY; DRUG DESIGN; HIV INTEGRASE; HIV-1; INTEGRASE INHIBITORS; PROTEIN BINDING; QUINIC ACID; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS INTEGRATION; VIRUS REPLICATION;

EID: 80053211085     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. Vitoria M, Granich R, Gilks CF, et al. The global fight against HIV/AIDS, tuberculosis, and malaria: current status and future perspectives. Am J Clin Pathol. 2009;131(6):844-848.
2. Kallings LO. The first postmodern pandemic: 25 years of HIV/AIDS. J Intern Med. 2008; 263(3):218-243. (Pubitemid 351207350)
3. Hazra R, Siberry GK, Mofenson LM. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Annu Rev Med. 2009 Jul 21;[Epub ahead of print].
4. UNAIDS, WHO (December 2007). AIDS epidemic update. 2007;http://data. unaids.org/pub/EPISlides/2007/2007-epiupdate-en.pdf. Last accessed February 12, 2009.
5. Kilmarx PH. Global epidemiology of HIV. Curr Opin HIV AIDS. 2009;4(4):240-246.
6. Weiss RA. How does HIV cause AIDS? Science. 1993;260(5112):1273-1279. (Pubitemid 23231970)
7. Matsushita S. Current status and future issues in the treatment of HIV-1 infection. Int J Hematol. 2000;72(1):20-27.
8. Prajapati DG, Ramajayam R, Yadav MR, Giridhar R. The search for potent, small molecule NNRTIs: A review. Bioorg Med Chem. 2009;15;17(16):5744-5762.
9. Naider F, Anglister J. Peptides in the treatment of AIDS. Curr Opin Struct Biol. 2009;19(4):473-482.
10. Semenova EA, Marchand C, Pommier Y. HIV-1 integrase inhibitors: update and perspectives. Adv Pharmacol. 2008;56:199-228.
11. Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, Perno CF. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev. 2009;11(1):17-29.
12. Goldgur Y, Craigie R, Cohen GH, et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc Natl Acad Sci USA. 1999;96(23):13040-13043.
13. Singh IP, Bharate SB, Bhutani KK. Anti-HIV natural products. Current Science. 2005;89(2):269-290. (Pubitemid 41666823)
14. Robinson WE Jr, Reinecke MG, Abdel-Malek S, Jia Q, Chow SA. Inhibitors of HIV-1 replication that inhibit HIV integrase. Proc Natl Acad Sci USA. 1996;93(13):6326-6331. (Pubitemid 26230304)
15. Zhu K, Cordeiro ML, Atienza J, Robinson WE Jr, Chow SA. Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids. J Virol. 1999;73(4):3309-3316. (Pubitemid 29135724)
16. Hu Z, Southerland W. WinDock: Structure-based drug discovery on Windows-based PCs. J Comp Chem. 2007;28(14):2347-2351. (Pubitemid 47389147)
17. Ewing TJ, Makino S, Skillman AG, Kuntz ID. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des. 2001;15(5):411-428. (Pubitemid 32452109)
18. Thomsen R, Christensen MH. MolDock: a new technique for high-accuracy molecular docking. J Med Chem. 2006;49(11):3315-3321. (Pubitemid 43830529)
19. Farnet CM, Wang B, Lipford JR, Bushman FD. Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules. Proc Natl Acad Sci USA. 1996;93(18):9742-9747. (Pubitemid 26296679)
20. Jenkins TM, Esposito D, Engelman A, Craigie R. Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photo-crosslinking. EMBO J. 1997;16(22):6849-6859. (Pubitemid 27503496)
21. Lubkowski J, Yang F, Alexandratos J, et al. Structure of the catalytic domain of avian sarcoma virus integrase with a bound HIV-1 integrase-targeted inhibitor. Proc Natl Acad Sci USA. 1998;95(9):4831-4836. (Pubitemid 28208511)
22. Robinson WE Jr, Cordeiro M, Abdel-Malek S, et al. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase. Mol Pharmacol. 1996;50(4):846-855. (Pubitemid 26347704)
23. Lawn SD. AIDS in Africa: the impact of coinfections on the pathogenesis of HIV-1 infection. J Infect. 2004;48(1):1-12. (Pubitemid 38072197)
24. Schneider MF, Gange SJ, Williams CM, et al. Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS. 2005;19(17):2009-2018. (Pubitemid 41669026)
25. Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, Whitworth JA. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS. 2002;16(4):597-603. (Pubitemid 34218855)